Russ Altman, MD, PhD

Former Chairman, BioEngineering Department Stanford University and Principal Investigator, PharmGKB
Russ Biagio Altman is Professor of Bioengineering, Genetics, & Medicine (and of Computer Science, by courtesy) and former Chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing technology to basic molecular biological problems of relevance to medicine. He is particularly interested in informatics methods for advancing pharmacogenomics, the study of how human genetic variation impacts drug response (e.g. http://www.pharmgkb.org/). Other work focuses on the analysis of functional sites within macromolecules with a focus on understanding the action, interaction, and adverse events of drugs.Dr. Altman holds an M.D. from Stanford Medical School, a Ph.D. in Medical Information Sciences from Stanford, and an A.B. from Harvard College. He has been the recipient of the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians, the American College of Medical Informatics, and the American Institute of Medical and Biological Engineering. He is a past-president, founding board member, and a Fellow of the International Society for Computational Biology. He is an organizer of the annual Pacific Symposium on Biocomputing. He leads one of seven NIH-supported National Centers for Biomedical Computation, focusing on physics-based simulation of biological structures. He won the Stanford Medical School graduate teaching award in 2000. He is a member of the Institute of Medicine of the National Academies.  Dr. Altman chairs the FDA Science Board advising the Commissioner 2013-2014, and is the President-Elect of the American Society for Clinical Pharmacology & Therapeutics.

[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Euan Ashley, MD, PhD

Associate Professor of Medicine (Cardiovascular) and Director of Stanford Center for Inherited Cardiovascular Disease, Stanford University

Euan Ashley BSc (Hons), MB ChB, MRCP, DPhil, FACC, FAHA
Associate Professor of Medicine (Cardiovascular),
Director, Stanford Center for Inherited Cardiovascular Disease
Co-Director, Training Program in Myocardial BiologyMember, Institute of Medicine Roundtable on Translating Genomic-based Research for Health
Director, Stanford Cardiopulmonary Exercise Testing Laboratory
Leadership committee, AHA Council on Functional Genomics and Translational Biology
Director, Stanford Hypertrophic Cardiomyopathy Center

Born and raised in Scotland, Dr Ashley graduated with 1st class Honors in Physiology and Medicine from the University of Glasgow. He completed medical residency and received a PhD in molecular cardiology at the University of Oxford before moving to Stanford University where he was a Donald W. Reynolds Fellow. He trained in clinical cardiology and advanced heart failure and joined the faculty in 2006. His laboratory is focused on the application of genomics to medicine. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The paper, published in the Lancet, was reported in over 300 news stories worldwide and became one of the most cited articles in clinical medicine that year. The team extended the approach in 2011 to a family of four and now routinely apply genome sequencing to the diagnosis of patients at Stanford hospital where Dr Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. In 2013, Dr Ashley was recognized at the White House Data to Knowledge to Action event for his contributions to Personalized Medicine. Dr Ashley is a recipient of the National Innovation Award from the American Heart Association and a National Institutes of Health Director’s New Innovator Award. He is a member of the AHA Council on Functional Genomics, and the Institute of Medicine (IOM) of the National Academy of Sciences Roundtable on Translating Genomic-Based Research for Health. He is a peer reviewer for the NIH and the AHA as well as journals including the New England Journal of Medicine and the Lancet. He is co-founder of Personalis, Inc.

Father to two young Americans, in his ‘spare’ time, he tries (and usually fails) to understand baseball, plays the saxophone in a jazz quartet, and conducts research on the health benefits of single malt Scotch whisky.

Atul Butte, MD, PhD

Chief, Division of Systems Medicine, Department of Pediatrics, Stanford University and Principal Investigator, Varimed

Atul Butte, MD, PhD is Chief of the Division of Systems Medicine and Associate Professor of Pediatrics, Medicine, and by courtesy, Computer Science, at Stanford University and Lucile Packard Children’s Hospital. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD in Health Sciences and Technology from Harvard Medical School and MIT.

The Butte Laboratory builds and applies tools that convert more than 300 billion points of molecular, clinical, and epidemiological data — measured by researchers and clinicians over the past decade — into diagnostics, therapeutics, and new insights into disease. Examples of this method includes work on cancer drug discovery published in the Proceedings of the National Academy of Science (2000), on type 2 diabetes published in the Proceedings of the National Academy of Science (2003), on fat cell formation published in Nature Cell Biology (2005), on obesity in Bioinformatics (2007), and in transplantation published in Proceedings of the National Academy of Science (2009). To facilitate this, the Butte Lab has developed tools to automatically index and find genomic data sets based on the phenotypic and contextual details of each experiment, published in Nature Biotechnology (2006), to re-map microarray data, published in Nature Methods (2007), to deconvolve multi-cellular samples, published in Nature Methods (2010), and to perform these calculations on the internet “cloud”, as published in Nature Biotechnology (2010). The Butte Lab has used these tools on publicly available molecular data to successfully find new uses for existing drugs, as published in back-to-back papers in Science Translational Medicine (2011). The Butte Lab has also been developing novel methods in comparing clinical data from electronic health record systems with gene expression data, as described in Science (2008), and was part of the team performing the first clinical annotation of a patient presenting with a whole genome, as described in the Lancet (2010). The Butte Laboratory currently has been funded by HHMI and under sixteen NIH grants.

Mia Levy, M.D., Ph.D.

Director Cancer Clinical Informatics and Assistant Professor of Biomedical Informatics and Medicine, Vanderbilt University, Principle Investigator, My Cancer Genome
Dr. Mia A. Levy is the Director of Cancer Clinical Informatics for the Vanderbilt-Ingram Cancer Center and an Assistant Professor of Biomedical Informatics and Medicine at Vanderbilt University.
Dr. Levy received her undergraduate degree in Bioengineering from The University of Pennsylvania in 1997 and her Medical Doctorate from Rush University in 2003. She then spent 6 years at Stanford University completing post-graduate training in Internal Medicine and Medical Oncology while completing her Ph.D. in Biomedical Informatics. She joined the faculty at Vanderbilt as an Assistant Professor in Biomedical Informatics and Medicine in August 2009. She is a practicing medical oncologist specializing in the treatment of breast cancer.
Dr. Levy’s research interests include biomedical informatics methods to support the continuum of cancer care and cancer research. Current research projects include informatics methods for 1) clinical decision support for treatment prioritization of molecular subtypes of cancer, 2) longitudinal clinical plan management, 3) image based cancer treatment response assessment using quantitative imaging, and 4) learning cancer systems. She is the principle investigator for MyCancerGenome.org, a publically available knowledge resource for genome directed cancer treatment selection.

Michael Snyder, PhD

Chairman, Genetics Department, Stanford University and Principal Investigator, Regulome
Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. These include the large-scale analysis of proteins using protein microarrays and the global mapping of the binding sites of chromosomal proteins. His laboratory built the first proteome chip for any organism and the first high resolution tiling array for the entire human genome.